Advertisement
AMGN vs LLY
Which Stock Would AI Choose? Amgen (AMGN) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- Amgen (AMGN) and Eli Lilly (LLY) both operate in the biotechnology and pharmaceutical sectors, with Amgen offering broader exposure across oncology, inflammation, and cardiovascular areas while Eli Lilly maintains a concentrated focus on diabetes, obesity, and neuroscience.
- Recent market activity shows both stocks experiencing pullbacks, with Amgen (AMGN) declining amid spillover effects from a competitor’s trial setback in the Lp(a) space and Eli Lilly (LLY) retreating from near-record levels amid broader sector rotation.
- Amgen (AMGN) reported solid second-quarter 2026 results with 10% revenue growth and raised full-year guidance, supported by pipeline advances including positive Phase 3 data for its IMDELLTRA combination in lung cancer.
- Eli Lilly (LLY) delivered robust 48% year-over-year revenue growth in the second quarter of 2026, driven by its GLP-1 franchise, and completed acquisitions to expand its neuroscience portfolio.
- Valuation metrics indicate Amgen (AMGN) trades at a lower forward price-to-earnings ratio compared with Eli Lilly (LLY), alongside a higher dividend yield, while Eli Lilly (LLY) exhibits stronger revenue growth momentum and higher profitability margins.
- Sector sentiment remains influenced by obesity-drug competition, regulatory developments, and macroeconomic factors affecting healthcare spending.
Introduction
Amgen (AMGN) and Eli Lilly (LLY) represent two prominent players in the biotechnology and pharmaceutical industries, each with distinct business models and growth trajectories. This comparison examines their recent performance, operational focus, and market positioning to assist institutional investors, portfolio managers, and active traders evaluating relative opportunities within the healthcare sector. The analysis highlights observable differences in revenue drivers, valuation, dividend profiles, and recent catalysts that may influence short- to medium-term positioning. Readers seeking data-driven insights into how these stocks have responded to shared industry dynamics will find the overview relevant for portfolio construction or tactical allocation decisions.
Amgen Overview and Recent Performance
Amgen (AMGN) is a biotechnology company with a diversified portfolio spanning oncology, inflammation, cardiovascular disease, and rare conditions. In recent weeks, the stock experienced downward pressure following disappointing Phase 3 results from a competitor’s Lp(a)-lowering program, which raised questions about the broader therapeutic class despite Amgen (AMGN) not directly participating in the trial. Despite the near-term volatility, the company posted second-quarter 2026 revenue of $10.1 billion, representing 10% year-over-year growth, and raised its full-year guidance. Key growth drivers including certain inflammation and oncology products contributed meaningfully. Pipeline updates included positive Phase 3 survival data for an IMDELLTRA combination regimen in extensive-stage small cell lung cancer. The stock has traded with a beta below 0.5, reflecting relatively lower volatility compared with some sector peers.
LLY Overview and Recent Performance
Eli Lilly (LLY) focuses primarily on diabetes, obesity, and neuroscience therapeutics, with its GLP-1 receptor agonist franchise serving as the dominant revenue driver. In recent market activity, the shares pulled back from record highs amid sector rotation and profit-taking, though the company continues to report strong underlying demand. Second-quarter 2026 revenue reached approximately $23 billion, up 48% year-over-year, supported by continued uptake of its flagship obesity and diabetes treatments. The company completed the acquisition of AtaiBeckley to bolster its neuroscience pipeline and announced additional deals in immunology. Profitability margins remain elevated, and the firm has raised revenue guidance for the full year. Eli Lilly (LLY) maintains a higher beta than Amgen (AMGN), consistent with its growth-oriented profile and sensitivity to sentiment around the obesity-drug category.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of the platform’s AI trading bots that demonstrate strong suitability for prevailing market conditions. Tickeron offers hundreds of AI trading bots capable of trading thousands of different tickers across equities, options, and other instruments. Only those bots exhibiting favorable combinations of performance statistics, risk-adjusted returns, and alignment with current market regimes are featured in the trending section. Available bots span multiple trading styles, timeframes, and ticker universes, with historical win rates, profit factors, and drawdown metrics varying widely depending on strategy parameters. Traders can review detailed statistics for each bot to identify approaches that match their risk tolerance and objectives. Explore the curated selection on the Trending AI Robots page for additional insights.
Head-to-Head Comparison
Amgen (AMGN) and Eli Lilly (LLY) differ markedly in business concentration and growth profiles. Amgen (AMGN) maintains a more diversified revenue base across multiple therapeutic areas, which has contributed to steadier performance during periods of sector-specific volatility. Eli Lilly (LLY) derives the majority of its recent growth from the GLP-1 obesity and diabetes category, creating both substantial upside potential and heightened exposure to competitive and regulatory developments in that space. Valuation-wise, Amgen (AMGN) trades at a lower price-to-earnings multiple and offers a higher dividend yield, appealing to income-oriented investors, while Eli Lilly (LLY) commands a premium multiple reflecting its faster revenue expansion. Risk factors include Amgen (AMGN)’s exposure to biosimilar competition on legacy products and Eli Lilly (LLY)’s dependence on continued GLP-1 demand and manufacturing scale-up. Market sentiment has recently weighed on both names, though the catalysts differ: competitive trial readouts for Amgen (AMGN) versus profit-taking after strong runs for Eli Lilly (LLY).
Tickeron AI Verdict
Based on observable factors such as trend consistency, valuation differentials, dividend support, and relative stability in recent market activity, Tickeron’s AI models currently assign a modestly higher probabilistic preference to Amgen (AMGN) over Eli Lilly (LLY) for strategies emphasizing downside protection and income. Eli Lilly (LLY) retains strong growth momentum that could support outperformance in favorable risk-on environments. The assessment remains probabilistic and subject to ongoing data updates rather than a definitive ranking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and LLY is a Hold.
| AMGN | LLY | AMGN / LLY | |
| Capitalization | 208B | 1.03T | 20% |
| EBITDA | 17.6B | 41.7B | 42% |
| Gain YTD | 20.235 | 7.799 | 259% |
| P/E Ratio | 23.95 | 38.70 | 62% |
| Revenue | 38.1B | 79.7B | 48% |
| Total Cash | 14B | 8.95B | 156% |
| Total Debt | 57.3B | 54.9B | 104% |
AMGN | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 12 | 11 | |
SMR RATING 1..100 | 15 | 14 | |
PRICE GROWTH RATING 1..100 | 46 | 44 | |
P/E GROWTH RATING 1..100 | 32 | 69 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (6) in the Biotechnology industry is somewhat better than the same rating for LLY (50) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is in the same range as AMGN (12) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as AMGN (15) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
LLY's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as AMGN (46) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (32) in the Biotechnology industry is somewhat better than the same rating for LLY (69) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than LLY’s over the last 12 months.
| AMGN | LLY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 61% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 42% | 2 days ago 56% |
| MACD ODDS (%) | 2 days ago 40% | 2 days ago 44% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 47% | 2 days ago 58% |
| Advances ODDS (%) | 2 days ago 62% | 2 days ago 70% |
| Declines ODDS (%) | 9 days ago 47% | 9 days ago 54% |
| BollingerBands ODDS (%) | 2 days ago 58% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 62% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while LLY’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- LLY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 3 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 5 bearish.
- LLY’s TA Score: 3 bullish, 7 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.20% price change this week, while LLY (@Pharmaceuticals: Major) price change was +3.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.82%. For the same industry, the average monthly price growth was -6.21%, and the average quarterly price growth was +15.37%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
LLY is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.82% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GSPCX | 12.85 | 0.02 | +0.16% |
| Goldman Sachs Large Cap Equity C | |||
| ISCCX | 34.25 | -0.07 | -0.20% |
| Federated Hermes Intl Small-Mid Co C | |||
| CFIOX | 17.80 | -0.10 | -0.56% |
| Cantor Fitzgerald International Eq A | |||
| FCVIX | 21.04 | -0.13 | -0.61% |
| Fidelity Advisor Small Cap Value I | |||
| ARIIX | 10.86 | -0.11 | -1.00% |
| AB Global Real Estate Investment II I | |||